Scientists probe how eczema drug repairs Skin's protective shield
NCT ID NCT04447417
Summary
This study aimed to understand how the approved eczema medication dupilumab affects the skin's barrier function. It involved 52 patients with moderate to severe atopic dermatitis who received dupilumab, plus some healthy volunteers for comparison. Researchers used a special tape-stripping method to gently remove layers of skin cells and measure how well the skin holds in moisture before and after 16 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 1240001
Montreal, H2X 2V1, Canada
-
Investigational Site Number 8400001
Denver, Colorado, 80206, United States
Conditions
Explore the condition pages connected to this study.